ConductScience.org, home

Paper42424601

Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib.

Arakawa Y and 4 others. Cancer Res Commun, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib. Papers, record 42424601. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42424601

Download JSON
Cell line
U2OS443 papers
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib.
PubMed
Journal
Cancer Res Commun
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-23
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Multiple MyelomaMajor topic
BortezomibMajor topic
Nuclear ProteinsMajor topic
Cell NucleolusMajor topic
Humans
Cell Line, Tumor
Gene Expression Regulation, Neoplastic
Antineoplastic Agents

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
Z01 BC006150Intramural NIH HHSUnited StatesZ01BC006150PubMedNIH RePORTER
25K11676Japan Society for the Promotion of Science (JSPS)PubMedPubMed
Z01-BC-006150National Cancer Institute (NCI)Z01BC006150PubMedNIH RePORTER

Download CSV of grants

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Update of42051302Schlafen 11 (SLFN11) overexpression and nucleolar localization in response to bortezomib in multiple myeloma.https://conductscience.org/library/papers/42051302

Source PubMed

Download CSV of comments and corrections

References57

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132444850Visualizing and interpreting cancer genomics data via the Xena platform.Nat Biotechnol2020https://conductscience.org/library/papers/32444850PubMed
222927417Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents.Proc Natl Acad Sci U S A2012https://conductscience.org/library/papers/22927417PubMed
325779942SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.Clin Cancer Res2015https://conductscience.org/library/papers/25779942PubMed
431128155Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies.Pharmacol Ther2019https://conductscience.org/library/papers/31128155PubMed
533863777SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243.Cancer Res2021https://conductscience.org/library/papers/33863777PubMed
634808009Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy.Cancer Sci2022https://conductscience.org/library/papers/34808009PubMed
735143610blitzGSEA: efficient computation of gene set enrichment analysis through gamma distribution approximation.Bioinformatics2022https://conductscience.org/library/papers/35143610PubMed
834294893A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers.Br J Cancer2021https://conductscience.org/library/papers/34294893PubMed
935768579Structural, molecular, and functional insights into Schlafen proteins.Exp Mol Med2022https://conductscience.org/library/papers/35768579PubMed
1029444873Hypoxia-inducible KDM3A addiction in multiple myeloma.Blood Adv2018https://conductscience.org/library/papers/29444873PubMed
1115491288Expression of protein gene product 9.5 (PGP9.5)/ubiquitin-C-terminal hydrolase 1 (UCHL-1) in human myeloma cells.Br J Haematol2004https://conductscience.org/library/papers/15491288PubMed
1233785877Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers.Br J Cancer2021https://conductscience.org/library/papers/33785877PubMed
1338753784DNA damage induces p53-independent apoptosis through ribosome stalling.Science2024https://conductscience.org/library/papers/38753784PubMed
1417692103Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.Eur J Haematol2007https://conductscience.org/library/papers/17692103PubMed
1539185596Immunohistochemical Evaluation of Schlafen 11 (SLFN11) Expression in Cancer in the Search of Biomarker-Informed Treatment Targets: A Study of 127 Entities Represented by 6658 Tumors.Am J Surg Pathol2024https://conductscience.org/library/papers/39185596PubMed
1618174376Cell cycle-dependent chromatin loading of the Fanconi anemia core complex by FANCM/FAAP24.Blood2008https://conductscience.org/library/papers/18174376PubMed
1731227499Targeting Topoisomerase I in the Era of Precision Medicine.Clin Cancer Res2019https://conductscience.org/library/papers/31227499PubMed
1820574050Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.Blood2010https://conductscience.org/library/papers/20574050PubMed
1930054467Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects.Nat Commun2018https://conductscience.org/library/papers/30054467PubMed
2038194610Genomic Classification and Individualized Prognosis in Multiple Myeloma.J Clin Oncol2024https://conductscience.org/library/papers/38194610PubMed

See all 57 referencesDownload CSV of references

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD1C911PubTator's text mininghttps://conductscience.org/library/genes/911NCBI Gene
MAF4094PubTator's text mininghttps://conductscience.org/library/genes/4094NCBI Gene
MAFB9935PubTator's text mininghttps://conductscience.org/library/genes/9935NCBI Gene
MKI674288PubTator's text mininghttps://conductscience.org/library/genes/4288NCBI Gene
SDC16382PubTator's text mininghttps://conductscience.org/library/genes/6382NCBI Gene
SLFN1191607PubTator's text mininghttps://conductscience.org/library/genes/91607NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42424601

GET https://conductscience.org/api/papers/v1/42424601/references?page=2